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Eliminating vaccine-preventable diseases is one of the major steps in the reduction of under five mortality and the importance of vaccines has always been appreciated since 
ancient times. First vaccine (smallpox) was discovered in 1798 while 
India received its share of the first smallpox vaccine in May 1802, 
from England. Import of smallpox vaccine continued until 1880 
when India started manufacturing its vaccine and vaccine institutes 
were set up like Haffkine institute, Central Research Institute and 
Pasteur’s Institute at Shillong. Trials on cholera vaccine, plague 
vaccine, and typhoid vaccine continued till 1908 [1-4].
During the early 20th century, there were various developments 
on the political front such as first world war (1914–1918) and 
cholera outbreak (1896–1907), which led India to shift its an 
impetus to controlling these events and vaccination took a back 
seat. Vaccines received priority after Indian Independence.
TUBERCULOSIS (TB)
After independence, it was noticed that a maximum number 
of smallpox cases in the world was being reported by India. 
A Bacillus Calmette Guerin (BCG) vaccine laboratory at King 
Institute, Madras (now Chennai), was established in 1948 
and with the support of International TB Campaign till 1957 
and later on with the support by United Nations International 
Children’s Emergency Fund (UNICEF), mass vaccination 
campaign was conducted and BCG vaccination became part of 
National TB control program in 1962 along with establishment 
of TB chemotherapy center in 1956 which was later renamed as 
National Institute for Research in TB. A large BCG trial named 
as “Feasibility study for TB prevention trial” was conducted in 
Chingelput in 1968 with 15 years follow-up till 1987 and this 
trial was a success which gave India the confidence of conducting 
large vaccination trials [5].
SMALLPOX
During this period from 1950 onward on the global front, 
smallpox eradication was the target and this was announced 
by the World Health Assembly (WHA) in 1958. India started 
National Smallpox Eradication in 1962 with the aim of 80% 
vaccination coverage, and the decision was taken to continue 
with vaccination in children <15 years of age. There was a 
revision in smallpox eradication strategy with importance being 
laid on surveillance and investigation of the outbreak. With 
the help of intensive campaigns in 1973, India became free of 
smallpox with the last case reported in 1975 and was declared 
free of smallpox in 1977 by the World Health Organization 
(WHO) [6].
Eradication of smallpox gave the nation a trained workforce 
and confidence to control these vaccine-preventable disease. 
With this positive reinforcement, India adopted expanded 
program on immunization (EPI) in 1978 to cover six vaccine-
preventable disease diphtheria, whooping cough, tetanus, polio, 
TB, and typhoid but later typhoid vaccine was excluded due to 
low disease burden and lower efficacy of the vaccine. Measles 
was included in EPI in 1985, and EPI was renamed as universal 
immunization program and was launched in 31 districts of India 
and universalized to cover the whole country in 1990.
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In 1988, the WHA took a resolution to eradicate polio in 2000. 
India’s vaccination target was shifted to polio eradication with 
stress on routine immunization, pulse polio, and surveillance 
with the last case of wild poliovirus reported in 2011. In 2012, 
the WHO removed India from the list of polio-endemic countries.
MEASLES AS BURDEN ON GLOBAL FRONT
On the global front, since polio is at the verge of eradication, 
measles elimination is the next target. Efforts toward achieving 
this target have been continuing for a long time. The burden of this 
disease is very large as, in the year 2000, (WHO) estimated that 
535,000 children died of measles and United Nation Millennium 
Development Goals (MDG) were framed with MDG4 targeting 
reduction of an overall number of deaths among children by 
2/3rd between 1990 and 2015. Routine measles vaccination 
(MCV) coverage is an indicator of progress toward the goal [7-9].
Measles initiative now known as measles-rubella (MR), 
initiative was launched in 2001 to support technically and 
financially measles control activities, and this was restricted to 
control in Eastern Europe. Various partners of the initiative are 
American Red Cross, United States Centre for Disease Control 
(CDC) and prevention, UNICEF, United Nation Foundation, 
and WHO [10]. Measles elimination has already been achieved 
in America in 2002. After the experience of America now 
MR initiative wants to extend measles elimination to all other 
regions of the world and a strategic plan has been made with 
a target of measles elimination and rubella control by 2020. 
Recommendations and guidance by the Strategic Advisory Group 
of Experts on immunization and Global Immunization Vision and 
Strategic plan have been incorporated into the strategic plan [11].
Various goals and milestones of the plan for 2015 were as 
follows:
1. To reduce global measles mortality in 2015 by at least 95% 
compared with the year 2000.
2. To reduce annual measles incidence to <5 cases per million.
3. To achieve at least 90% coverage with the first dose of 
measles-containing vaccine nationally and 80% vaccination 
coverage in every district.
4. To achieve at least 95% coverage with the MR vaccine during 
supplementary immunization activities.
5. To establish a Rubella/congenital rubella syndrome (CRS) 
elimination goal in at least three additional the WHO regions.
6. Establish a target date for global eradication of measles.
 Further, the roadmap by the end of 2020 is as follows:
1. To sustain achievement of 2015 goals.
2. To achieve at least 95% coverage by both first and second 
routine doses of measles in each district.
3. Establish the target date for global eradication of rubella and 
CRS.
Measles elimination being defined as the absence of endemic 
measles virus transmission in a region or other defined geographic 
area for ≥12 months in the presence of high-quality surveillance 
system.
If we go by the achievements in measles control from 2000 to 
2016, then there has been substantial progress. Annual measles 
incidence has decreased by 87% from 145 to 19 cases/million 
persons, and annual estimated measles death decreased by 84% 
from 550,100 to 89,780, and around 20.4 million deaths were 
prevented by MCV [12]. These targets have been achieved due 
to the increase in MCV coverage because measles first dose 
(MCV1) coverage has increased from 72% to 88% but has 
remained at 83–84% till 2013. The incidences of measles have 
also increased to 33 cases/million population in 2012 which was 
mainly due to outbreaks reported in Nigeria, China, Pakistan, 
Angola, Indonesia, Uganda, Georgia, and Turkey. Moreover, it 
is still a long way to go as 20.8 million infants did not receive 
MCV1 through routine immunization, and they belonged to 6 
countries with suboptimal coverage with India accounting for 
2.9 million unvaccinated infants [11-13].
MEASLES BURDEN ON INDIAN FRONT
India was aware of the importance of MCV even in 1978 before 
MCV became part of EPI in 1985 as a comparison study was 
conducted in Vellore between vaccinated and unvaccinated 
children during epidemic of measles where attack rate and case 
fatality rate were 26% and 14% in vaccinated children while in 
unvaccinated children attack rate and case fatality rate were 37% 
and 20%, respectively. The vaccine was received from Rotary 
International with special Central government’s permission [14].
Another extensive two-phase study was carried out by 
Kaur et al. from September 1979 to March 1980 in Varanasi, 
for establishing the age of MCV in infants based on measles 
antibody titers. In the first phase of the study, 162 newborns were 
enrolled and cord samples for measles antibody were measured. 
It was found that seronegative infants with antibody titer below 
1:4 rose from 1 month to 6 months of age as there were 4.17% 
seronegative infants <1 month of age while 38.89% of infants 
were seronegative at 6 months of age. This fall in antibody 
titers was very rapid after 4 months of age making infants more 
susceptible to infection.
In the 2nd phase of the study, 107 infants were enrolled for 
MCV and then were followed up for measles antibody titer at 
1 month, and data of 62 infants were analyzed. It was concluded 
that vaccination at 8 months was the optimum time for vaccination 
as 100% of infants showed four-fold rise in antibodies when 
vaccinated between 8 and 15 months of age. It was further 
concluded that high pre-immunization antibody titers interfered 
with seroconversion later [15,16].
MEASLES OUTBREAKS
Even after the introduction of MCV in EPI, India was not 
manufacturing MCV till 1990–91. After the introduction of 
MCV, there has been a decrease in the incidence of measles 
from 161,216 cases to 36,711 in 2005 and coverage increased 
from 1% to 59%. In 2006 though coverage increased to 71% as 
per the WHO data there was an increase in a number of cases to 
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64,185 which was due to the outbreaks in 2004–2006. One of 
the outbreak investigations between 2004 and 2006 conducted in 
Himachal Pradesh, West Bengal, and Uttaranchal concluded that 
measles outbreaks were noted at younger age and attack rate was 
higher in an area with lesser immunization coverage compared to 
areas with higher immunization coverage. After the introduction 
of national measles surveillance and outbreak investigation in 
2005 total suspected measles outbreaks investigated in 2010 were 
242 and confirmed outbreaks were 198 while in 2011 there were 
109 confirmed measles outbreaks [17,18].
MEASLES CAMPAIGNS
The WHA in 2010 committed to reduce 95% of measles death 
in 2015 from the levels reported in 2010. It was discovered that 
though measles mortality had declined by 74% from 535,000 
deaths in 2000 to 139,300 in 2010, but Southeast Asian regions 
were still having high mortality and 47% of measles mortality 
in 2010 was reported from India. The main reason for this was 
delayed implementation of measles control activity, and this could 
be increased by the introduction of a 2nd dose of MCV which was 
done in 2010. India was the last country to introduce MCV2 
into the national immunization program. This introduction of 
MCV2 was done into routine immunization in 21 states with high 
immunization coverage and through supplementary immunization 
coverage/campaign in states with low immunization coverage. 
These campaigns were carried out in a phased manner. Measles 
campaign was carried out in 14 States in 3 phases. In phase 1 
from November 2010 to March 2011, 45 districts from 13 states 
(Chattisgarh, Bihar, Jharkhand, Meghalaya, Rajasthan, Madhya 
Pradesh, Gujarat, Haryana, Manipur, Assam, Arunachal Pradesh, 
Nagaland, and Tripura) were covered. Uttar Pradesh was covered 
in the 2nd phase [17,19].
This campaign lasted three weeks, i.e., 12 working days. 
1st week which was school-based campaign (5–10 years old 
children), 2nd and 3rd weeks being community-based campaign. 
Coverage was estimated to be 87.2% in this campaign, and 
>90% coverage was seen in 18 districts. In the 2nd phase between 
2011 and 2012, 14 states (Arunachal Pradesh, Assam, Bihar, 
Chhattisgarh, Gujarat, Haryana, Jharkhand, Madhya Pradesh, 
Manipur, Meghalaya, Nagaland, Rajasthan, Tripura, and 
Uttar Pradesh) were covered and coverage was 90% while in 
phase three between 2012 and 2013, 5 states were covered and 
coverage was 82.6% [20].
As per National Family Health Survey (NFHS) -1 (1992–93), 
MCV coverage was 42% while in NFHS -2 (1998–99), MCV 
coverage was 51% which increased to 58.8% in NFHS-3 (2005–06) 
and the coverage increased drastically as per the NFHS-4 (2015–
16) to 81.1%. This increase in coverage could be due to the mass 
campaigns carried out in 2010–11 [21-24].
These campaigns were helpful in controlling the cases of 
measles and number of cases fell from 10,308 annually in 2010 to 
3314 in 2012 but again there was an increase in cases in 2013 and 
2014 to 10,059, the reason being the outbreaks. There were around 
71 outbreaks in 2013 and 87 in 2014. Even the immunity has 
waned after 2013 campaigns, and there is a need of campaigning 
again in these areas which will help in achieving elimination 
of measles by 2020 [16]. In 2014 National Technical Advisory 
Group on Immunization also recommended the introduction of 
MR vaccine in phased manner from 2017 to 2018 to cover all the 
36 states and after the campaign replace MCV with MR vaccine 
at 9 months and 15–18 months because it has been realized that 
replacing of MCV with MR vaccine would add to only increase 
in cost by the US $ 0.3 per dose for MR vaccine and would save 
the cost of treatment of single CRS case which is around the 
US $ 75000 [25]. India’s MCV coverage was varied depending 
on the regions.
If we go by the data of NFHS-4 maximum coverage of MCV 
is seen in southern states, followed by the northern states and 
minimum coverage are seen in northeastern states. In southern 
region, all the states have >75% coverage while in northeastern 
region only Sikkim has good coverage, i.e., 93.3% while rest of 
the states have coverage of <75% with least coverage being of 
Arunachal Pradesh (54.6%) and Nagaland (50.1%) [24].
India introduced a national level MR campaign in 2017 in a 
phased manner with the first phase completed in 5 states, namely, 
Goa, Karnataka, Lakshadweep, Pondicherry, and Tamil Nadu. The 
second phase was launched in August 2017 in 8 states - Kerala, 
Himachal Pradesh, Uttarakhand, Chandigarh, Andhra Pradesh, 
Dadra and Nagar Haveli, and Daman and Diu. Third phase was 
started on January 30, 2018, in Odisha and aim is to cover 12 
states till March. The last phase would include Punjab in April-
May, 2018 [21]. This campaign would target children from the 
age group of 9 months to 15 years and would be 1 week for school 
vaccination followed by outreach teams for 2nd and 3rd weeks and 
mobile teams for strengthening the outreach areas. Sweeping 
activity to cover left out/suboptimal coverage area will be done 
in 4th week [25].
The team includes one vaccinator auxiliary nurse-midwifery, 
one accredited social health activist, one Anganwadi Worker, 
and local volunteer. The aim is to vaccinate 100–150 children/
vaccinator per day at the outreach center and 150–200 children/
vaccinator in school session site. An adverse event following 
immunization (AEFI)is reported and given special attention [25].
CAMPAIGN - COMMITTEES AND EXECUTION
MR campaign involves a lot of planning at the national, state, and 
district level. At national level there is steering committee which 
is chaired by secretary health and family welfare, Government 
of India which has a role of coordination of activities among 
Government ministries, departments, institutes such as National 
Institute of Health and Family Welfare (NIHFW), National Cold 
Chain and Vaccine Management Resource Centre, National 
Health Mission (NHM), National CDC, Education, Women 
and Child Development social welfare, Department of Health 
Research (DHR), AYUSH, Home Affairs, defence, and Youth 
Affairs. [25].
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Another committee at the national level is central operations 
group chaired by Joint Secretary (RCH) DC- immunization 
which comprises officials from Government of India, WHO 
India, UNICEF, NIHFW, and other partners [25]. A control 
room is established at immunization division Immuniszation 
Technical Support Unit (ITSU) under MOHFW for planning, 
monitoring, coordination, and implementation of activities 
during the MR campaign with members of CDG [25]. At state 
level there is State Steering Committee under chairmanship of 
State Chief Secretary and this committee involves mobilizing 
human and other resources and coordination, planning 
and implementation of activities along with Government 
departments such as education, social welfare, NHM, DHR, 
AYUSH, and Home Affairs and partner coordination with 
WHO India, UNICEF, Red Cross, ITSU, State Reproductive 
Maternal, Newborn Child and Adolescent Health, IMA, IAP, 
National professional bodies of Public Health, Paediatrics, and 
other departments of medical college and civil societies such as 
Rotary Lions and GAV1 [25].
During the campaign, a state control room is established for 
day to day monitoring and management of human resources. At 
district level, there is a district task force for immunization under 
the chairmanship of District Collector/Magistrate in each District 
and Chief Medical Officer/District Immunization Officer (DIO) 
would be members.
There is district task force meetings and establishment of 
the control room during the campaign at district level [25]. 
Preparedness at district level along with coordination with 
other departments, sensitizing school principals, microplanning, 
training, supervision, communication cold chain, interdepartmental 
coordination, and AEFI management and release of funds under 
the leadership of civil medical officer/district health officer is 
executed.
DIO ensures completion and review of the micro-plans 
along with training of vaccinators [25]. In Punjab MR 
campaign was held in May 2018 in phase four along with 
other states Haryana, Assam, Mizoram, and Andaman and 
Nicobar Islands where it was estimated that 75 lacs children 
were vaccinated. Results after supplementary immunization 
activity and MR Campaigns in India during 2017–2018 
have shown that there has been a decline in the number of 
confirmed cases of Measles from 57,392 in 2017 to 38,505 in 
2018 till August. India plans to start to catch up immunization 
from January 2019 and target is to cover the population of 
49,300,000 [26].
CONCLUSION
India has traveled a very long distance from the introduction of 
vaccination and acquiring country’s own vaccine manufacturing 
to the eradication of one disease after the other. Measles campaigns 
in 2010–11 in selected states have increased the vaccination 
coverage of country drastically.
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